Long-Term Outcome of Treatment With Protocols AL841, AL851, and ALHR88 in Children With Acute Lymphoblastic Leukemia: Results Obtained by the Kyushu-Yamaguchi Children’s Cancer Study Group

2001 ◽  
Vol 73 (3) ◽  
pp. 369-377 ◽  
Author(s):  
Akinobu Matsuzaki ◽  
Eiichi Ishii ◽  
Yoshihisa Nagatoshi ◽  
Haruhiko Eguchi ◽  
Hiroyuki Koga ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Study Group ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Cancer Study ◽  
Cancer Study Group

Long-term outcome in children with Hodgkin’s lymphoma: The United Kingdom Children’s Cancer Study Group HD82 trial

2007 ◽  
Vol 43 (7) ◽  
pp. 1171-1179 ◽  
Author(s):  
Michael Capra ◽  
Martin Hewitt ◽  
Martin Radford ◽  
Janis Hayward ◽  
Claire L. Weston ◽  
...  
Keyword(s):  
United Kingdom ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Cancer Study ◽  
The United Kingdom ◽  
Cancer Study Group

Effects of radiation on ovarian function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.

1987 ◽  
Vol 5 (11) ◽  
pp. 1759-1765 ◽  
Author(s):  
M R Hamre ◽  
L L Robison ◽  
M E Nesbit ◽  
H N Sather ◽  
A T Meadows ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Ovarian Function ◽  
Lymphoblastic Leukemia ◽  
Pubertal Development ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Sexual Characteristics

The Childrens Cancer Study Group has assessed serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), and pubertal development in 97 long-term female survivors of childhood acute lymphoblastic leukemia (ALL). All patients received identical induction and maintenance therapy with either 18 or 24 Gy of radiation therapy (RT) to one of the following fields: cranial, craniospinal, or craniospinal plus 12 Gy abdominal RT including the ovaries. Thirty-six percent (35 patients) were found to have above normal levels of FSH and/or LH. The percentages of elevated values for RT fields were 93% for craniospinal plus abdominal RT, 49% for craniospinal RT, and 9% for cranial RT (P less than .001). A dose-response relationship was observed between 18 Gy and 24 Gy in females receiving only craniospinal RT (P = .01). Craniospinal plus abdominal RT and abnormal FSH/LH levels were significantly associated with lack of pubertal development and delayed onset of menses. Duration of maintenance chemotherapy was not associated with abnormal gonadotropin levels or the development of secondary sexual characteristics. Additional follow-up of this cohort is needed to establish the ultimate pubertal development and fertility of these patients.

Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.

1989 ◽  
Vol 7 (3) ◽  
pp. 316-325 ◽  
Author(s):  
D R Miller ◽  
S L Leikin ◽  
V C Albo ◽  
H Sather ◽  
G D Hammond
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Complete Remission ◽  
Maintenance Therapy ◽  
Lymphoblastic Leukemia ◽  
Disease Free Survival ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Discontinue Therapy ◽  
The Difference

Childrens Cancer Study Group protocol 141 (CCG-141), a randomized trial, was designed in part to compare 3 v 5 years of maintenance therapy, to evaluate the role of late reinduction, and to identify factors that predict relapse after 3 years of continuous complete remission (CCR) in acute lymphoblastic leukemia (ALL). Of 880 patients entered on study, 827 (94%) achieved complete remission and 499 (56.7%) were in CCR after 3 years of maintenance therapy. Boys were required to have negative testicular biopsies before randomization. A total of 481 patients were eligible for the duration of therapy phase of the study. Of the 310 (64.4%) randomly assigned patients, 101 were entered on regimen A: discontinue therapy; 105 on regimen B: reinduction for 4 weeks, then discontinue therapy; and 104 on regimen C: continue maintenance therapy for 2 more years, then discontinue. After a median follow-up of over 72 months, no significant differences in disease-free survival (DFS) or survival were noted in the three regimens. At 6 years from randomization, 93.0%, 89.1%, and 89.1% of patients on regimens A, B, and C, respectively, remained in CCR. Isolated CNS or overt testicular relapses were not significantly different in any of the study regimens. Isolated testicular relapse after a negative biopsy occurred in only two of 137 randomized males (1.5%). DFS (P = .10) and survival (P = .83) were not significantly different for all boys and girls randomized to regimens A, B, or C. The relapse rate was higher in boys than in girls randomized to discontinue therapy (11% v 4%), but the difference was not statistically significant (P = .14). Except for the presence of occult testicular leukemia (TL) in males, no other factors were identified that predicted for adverse events after 3 years of CCR. We conclude that prolongation of maintenance therapy beyond 3 years does not improve survival or decrease the risk of relapse.

Sign in / Sign up

Export Citation Format

Share Document